^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Cancer

    Related cancers:
    19h
    Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation. (PubMed, Cancer Immunol Immunother)
    Together, these data suggest that the IL-33/ST2 pathway may be involved in the crosstalk between the tumour and immune cells by modulating the phenotype of head and neck SCC and T cell activity. IL-33 neutralisation may offer a novel therapeutic strategy for SCC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL4 (Interleukin 4) • IL33 (Interleukin 33)
    |
    MYC expression
    20h
    Endometrial Cancer in a Family With RAD51D Gene Mutation. (PubMed, Int J Gynecol Pathol)
    We report a family of French Canadian ancestry with a germline mutation in RAD51D and two sisters presenting with endometrial carcinoma, endometrioid-type. The risk factors for endometrial adenocarcinoma, endometrioid-type are discussed in the context of the RAD51-associated carcinomas described to date.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • RAD51D (RAD51 paralog D)
    |
    HRD • RAD51D mutation • RAD51 mutation
    20h
    Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. (PubMed, Int J Gynecol Pathol)
    AR was detected in 95% of samples tested with antibodies derived from clone AR27. This detection rate is much higher than previously reported.
    Journal
    |
    PGR (Progesterone receptor) • AR (Androgen receptor)
    |
    AR expression
    21h
    TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1. (PubMed, FASEB J)
    Moreover, platinum treatment increased the cytoplasm proportion of TCEB3, and the cytoplasm localization of TCEB3 is important for its targeting of MCL-1. This study emphasizes the dual function of TCEB3 in homeostasis maintenance and in cell fate determination under different conditions, and provides a new insight into drug resistance in ovarian cancer.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1)
    |
    MCL1 expression
    23h
    Uncovering hidden genetic risk factors for breast and ovarian cancers in BRCA-negative women: a machine learning approach in the Saudi population. (PubMed, PeerJ Comput Sci)
    It specifically highlights genes associated with antigen processing and presentation, such as HLA-B, HLA-A and HLA-DRB1 and their possible effects on tumour progression and immune evasion. In summary, by utilizing machine learning approaches, we have the potential to aid in the development of precision medicine approaches for early detection and personalized treatment strategies.
    Journal • BRCA Biomarker • Machine learning
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    23h
    Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, AstraZeneca | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib)
    23h
    Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (clinicaltrials.gov)
    P2, N=531, Recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2026 | Trial primary completion date: Mar 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases
    |
    Avastin (bevacizumab) • carboplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine • leucovorin calcium • datopotamab deruxtecan (DS-1062a) • saruparib (AZD5305) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    24h
    A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Zhejiang University
    New P1 trial
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide
    1d
    Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, University of Alabama at Birmingham | N=20 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    1d
    ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC. (PubMed, Cell Death Dis)
    We generated isogenic clones of treatment-naïve and cisplatin-tolerant persister HGSOC cells...Moreover, analysis of TCGA data from 259 HGSOC patients revealed a significant progression-free survival advantage for patients with low expression of the ATF3-associated partial EMT genes. These findings suggest that increased ATF3 expression together with partial EMT promote the development of aggressive DTP, and thereby relapse in HGSOC patients.
    Journal
    |
    ITK (IL2 Inducible T Cell Kinase) • ATF3 (Activating Transcription Factor 3)
    |
    cisplatin
    1d
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab) • albumin-bound paclitaxel • Partruvix (pamiparib)
    1d
    Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis. (PubMed, Int J Gynecol Cancer)
    ctDNA was significantly associated with worse progression-free survival and overall survival in patients with epithelial ovarian cancer. Further prospective studies are needed.
    Retrospective data • Review • Journal • Circulating tumor DNA
    |
    HOXA9 (Homeobox A9)
    1d
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries. (PubMed, Gynecol Oncol)
    Most individuals with SLCT fare well, though specific risk factors such as mesenchymal heterologous elements are associated with poor prognosis. We also highlight the role of DICER1 surveillance in early detection of SLCT, facilitating stage IA resection.
    Journal • Stroma
    |
    DICER1 (Dicer 1 Ribonuclease III)
    1d
    A validated LC-MS/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients. (PubMed, J Pharm Biomed Anal)
    The validated method is currently employed to assess niraparib levels in human glioblastoma tissue, CSF, and plasma in an ongoing trial on newly diagnosed glioblastoma and recurrent IDH1/2(+) ATRX mutant glioma patients (NCT05076513). Initial results of calculated total (Kp) and unbound (Kp,uu) tumor-to-plasma partition coefficients indicate significant brain penetration ability of niraparib in glioblastoma patients.
    PK/PD data • Journal • PARP Biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ATRX (ATRX Chromatin Remodeler)
    |
    ATRX mutation
    |
    Zejula (niraparib)
    1d
    Platinum-induced upregulation of ITGA6 promotes chemoresistance and spreading in ovarian cancer. (PubMed, EMBO Mol Med)
    At molecular level, ITGA6 engagement regulates the production and availability of insulin-like growth factors (IGFs), over-stimulating the IGF1R pathway and upregulating Snail expression. In vitro data were recapitulated using in vivo models in which the targeting of ITGA6 prevents PT-resistant EOC dissemination and improves PT-activity, supporting ITGA6 as a promising druggable target for EOC patients.
    Journal
    |
    SNAI1 (Snail Family Transcriptional Repressor 1) • ITGA6 (Integrin, alpha 6)
    1d
    Mechanism of single-stranded DNA annealing by RAD52-RPA complex. (PubMed, Nature)
    RPA associates with RAD52 at the site of ring opening with critical interactions occurring between the RPA-interacting domain of RAD52 and the winged helix domain of RPA2. Our studies provide structural snapshots throughout the annealing process and define the molecular mechanism of ssDNA annealing by the RAD52-RPA complex.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • RAD52 (RAD52 Homolog DNA Repair Protein) • RPA2 (Replication Protein A2)
    1d
    The oncogenic role and regulatory mechanism of ACAA2 in human ovarian cancer. (PubMed, Mol Carcinog)
    ACAA2 regulated the malignant progression of ovarian cancer through the WNT/β-Catenin signaling pathway probably. ACAA2 is an oncogene in ovarian cancer and has the potential to be a target for ovarian cancer therapy.
    Journal
    |
    ACAA2 (Acetyl-CoA Acyltransferase 2)
    1d
    Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma. (PubMed, Histopathology)
    No abstract available
    Journal • Stroma
    |
    THBS2 (Thrombospondin 2)
    2d
    Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System. (PubMed, BMC Cancer)
    One in three women showed a pathogenic mutation, demonstrating a significant prevalence of germline mutations in this sample. Additionally, the small sample revealed an interesting number of mutations, indicating the need to explore more regions of the country.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    2d
    Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Sham Sunder Kakar | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2025 --> Nov 2026
    Enrollment open • Trial primary completion date • Combination therapy
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    |
    pegylated liposomal doxorubicin
    2d
    A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary (clinicaltrials.gov)
    P1/2, N=14, Terminated, Avenge Bio, Inc | Trial completion date: Aug 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2024; Sponsor Decision to close study
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    AVB-001
    2d
    A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=167, Not yet recruiting, Cancer Research UK
    New P1/2 trial • Combination therapy • Metastases
    2d
    Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach. (PubMed, J Ovarian Res)
    The five compounds that have been found can also be further examined as potential therapeutic possibilities. The combined findings suggest that ELAVL2, together with their genetic changes, can be investigated in therapeutic interventions for precision oncology, leveraging early diagnostics and target-driven therapy.
    Journal
    |
    ELAVL4 (ELAV Like RNA Binding Protein 4)
    2d
    A novel TCGA-validated programmed cell-death-related signature of ovarian cancer. (PubMed, BMC Cancer)
    Our model could precisely predict the prognosis, immune status and drug sensitivity of OC patients.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • RB1 (RB Transcriptional Corepressor 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CLTC (Clathrin Heavy Chain) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • OGG1 (8-Oxoguanine DNA glycosylase) • PPP1R15A (Protein Phosphatase 1 Regulatory Subunit 15A) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    cisplatin • gefitinib • paclitaxel • Erivedge (vismodegib)
    2d
    Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. (PubMed, Nat Med)
    PFS24 was associated with presence of MEGF8 or SETD1B somatic mutations. This trial met its co-primary endpoints (ORR and PFS24) early, and our findings highlight several genetic and tumor microenvironment parameters associated with response to PD-1 blockade in dMMR cancers, generating rationale for their validation in larger cohorts.ClinicalTrials.gov identifier: NCT03241745 .
    P2 data • Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SETD1B (SET Domain Containing 1B, Histone Lysine Methyltransferase) • MEGF8 (Multiple EGF Like Domains 8)
    |
    MSI-H/dMMR • MET mutation
    |
    Opdivo (nivolumab)
    2d
    Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=298, Recruiting, Acerand Therapeutics (Shanghai) Limited
    New P1/2 trial • Metastases
    2d
    Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer. (PubMed, Medicine (Baltimore))
    OC patients with low CRS score had a lower half maximal inhibitory concentration value of some drugs (Gemcitabine, Tamoxifen, and Nilotinib, etc) and lower score of some cancer-related hallmarks (Notch signaling, hypoxia, and glycolysis, etc). The current study developed an optimal CRS in OC, which acted as an indicator for the prognosis, stratifying risk and guiding treatment for OC patients.
    Clinical data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Machine learning
    |
    TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    gemcitabine • tamoxifen • Tasigna (nilotinib)
    2d
    Poorly differentiated mucinous carcinoma of the ascending colon complicated by bilateral ovarian mature cystic teratomas in a 17-year-old female patient: a case report. (PubMed, Surg Case Rep)
    We presented a case of locally advanced ascending colon cancer in a 17-year-old female patient. CRC rarely occurs in AYAs. However, the incidence has gradually increased in recent years. It should be considered as a differential diagnosis for young patients with long-term abdominal symptoms of unknown cause.
    Journal
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation
    |
    5-fluorouracil • oxaliplatin
    2d
    Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer. (PubMed, Cancer Chemother Pharmacol)
    Germline BRCA mutations were associated with a higher frequency of G2/3 anemia in ovarian cancer patients who underwent first-line platinum-based chemotherapy. Moreover, the BRCA1 mutation appeared to be more strongly associated with the incidence of chemotherapy-induced anemia. Our findings warrant further investigation in larger, prospective studies to confirm these current findings and determine whether preventive interventions may be necessary.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    2d
    Drug repositioning and ovarian cancer, a study based on Mendelian randomisation analysis. (PubMed, Front Oncol)
    By screening 31 drugs with 110 targets, FNTA, HSPA5, NEU1, CCND1, CASP1, CASP3 were negatively correlated with ovarian cancer, and HMGCR, PLA2G4A, ITGAL, PTGS1, FNTB were positively correlated with ovarian cancer. Statins (HMGCR blockers), lonafarnib (farnesyltransferase inhibitors), the anti-inflammatory drug aspirin, and the anti-malarial drug adiponectin all have potential therapeutic roles in ovarian cancer treatment.
    Journal
    |
    CCND1 (Cyclin D1) • CASP3 (Caspase 3) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • PTGS1 (Prostaglandin-Endoperoxide Synthase 1) • CASP1 (Caspase 1)
    |
    aspirin
    2d
    Diagnostic value of one-step nucleic acid amplification for sentinel lymph node metastasis in cytokeratin 19-positive tumors: evidence from bioinformatics and meta-analysis. (PubMed, Front Oncol)
    OSNA can predict the occurrence of SLN metastasis accurately in CK19 positive cancers, especially in breast cancer, colorectal cancer, lung cancer, gastric cancer and endometrial cancer. Our study warrants future studies investigating the clinical application of OSNA in pancreatic, ovarian and bladder cancers.
    Retrospective data • Review
    |
    KRT19 (Keratin 19)
    3d
    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p. (PubMed, Genes Environ)
    Astaxanthin significantly suppresses NPC cell proliferation, cell cycle arrest, migration, invasion while promoting cell apoptosis by inactivating PI3K/AKT and NF-κB pathways. The study first reveals the anticancer role of astaxanthin in NPC, providing a potential candidate for NPC treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • MIR29A (MicroRNA 29a)
    |
    LY294002
    3d
    Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer. (PubMed, J Transl Med)
    Collectively, these results suggested that MSLN-CAR T cells could potently eliminate MUC16- positive ovarian cancer tumor cells both in vitro and in vivo, thereby providing a promising therapeutic intervention for MUC16-positive patients.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 expression
    3d
    ALKBH5 modulates macrophages polarization in tumor microenvironment of ovarian cancer. (PubMed, J Ovarian Res)
    ALKBH5 participated in regulating macrophage M2 polarization in ovarian cancer immune microenvironment.
    Journal
    |
    ALKBH5 (AlkB Homolog 5, RNA Demethylase) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
    3d
    Primary lymphoma of the female genital tract masquerading as gynecological malignancy. (PubMed, BMC Womens Health)
    PLFGT usually presents as gynecological symptoms and solid masses in pelvis. Surgery or biopsy was the way to obtain the pathologic diagnosis, and combination chemotherapy is the efficient method for PLFGT. Making an accurate preoperative diagnosis is of paramount importance to avoid radical gynecologic surgery.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    3d
    Cukurova Score Validation Study (clinicaltrials.gov)
    P=N/A, N=130, Not yet recruiting, Cukurova University
    New trial • Metastases
    3d
    'OLAP' (OLAparib Regulatory Post-marketing Surveillance) (clinicaltrials.gov)
    P=N/A, N=650, Recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Lynparza (olaparib)
    3d
    Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging (clinicaltrials.gov)
    P1, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Apr 2024
    Enrollment open • Trial initiation date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSH2 (MutS Homolog 2)
    |
    BRCA2 mutation • BRCA1 mutation
    3d
    The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program (clinicaltrials.gov)
    P=N/A, N=78, Completed, Peking Union Medical College Hospital
    New trial
    3d
    Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov)
    P3, N=448, Recruiting, Mural Oncology, Inc | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • nemvaleukin alfa (ALKS 4230)
    3d
    Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer-Associated Germline Pathogenic Variants in Mexico. (PubMed, JCO Glob Oncol)
    Despite the resource-constrained setting, relevant rates of RR measures and CT were observed. Targeted interventions to reduce out-of-pocket expenses and improve patient-physician communication and patients' understanding on carrier status are warranted to enhance the overall benefit of GCRA and ultimately improve the provision of patient-centered care to both carriers and their at-risk relatives.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • NF1 (Neurofibromin 1) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C)
    3d
    Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. (PubMed, JCO Precis Oncol)
    The results of this follow-up analysis continue to support the promise of combined gemcitabine/ATRi therapy in platinum resistant ovarian cancer, an active area of investigation with several ongoing clinical trials.
    P2 data • Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    ATM expression
    |
    gemcitabine • berzosertib (M6620)